{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}],"title":"On-treatment deaths include post-treatment survival follow-up deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"}],"units":"Participants"}],"description":"On-treatment deaths, which include post-treatment survival follow-up deaths, were collected during the post-infusion period (starting at the day of first infusion) until the end of the study, approx. 61 months.\n\nAll deaths refers to the sum of on-treatment deaths and post-treatment survival follow-up deaths up to approx. 61 months.","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort"}],"paramType":"NUMBER","populationDescription":"Clinical Database Population: all infused participants in the Study.","reportingStatus":"POSTED","timeFrame":"On-treatment deaths: Up to 61 months; Post-treatment survival follow-up deaths: Up to approx. 61 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}